NAT1 (Arylamine N-Acetyltransferase 1, Arylamide Acetylase 1, Monomorphic arylamine N-Acetyltransferase, MNAT, N-Acetyltransferase Type 1, NAT-1, NAT1, AAC1) discontinued

Antibodies / Antibodies-Enzymes, Acetyltransferase

-20°C

Supplied as a liquid PBS,  0.1% sodium azide,  50% glycerol.

Recombinant full length Human NAT1.

Arylamine N-acetyltransferases (NAT-1 and NAT-2) catalyze N- or O-acetylation of heterocyclic and arylamine substrates in the detoxification of a wide array of drugs. Certain alleles causing high N-acetyltransferase activity have been associated with colon and urinary bladder cancers, as NATs also bioactivate several known carcinogens. Both NAT-1 and NAT-2 are cytoplasmic proteins and play an active role in the detoxification of many arylamine and hydrazine drugs. N-acetylation polymorphism is determined by the level of NAT activity in liver tissues, and has been linked to the action and toxicity of drugs that contain amines. Human NAT-1 is the functional homolog of rodent NAT-2, while human NAT-2 is the functional homolog of rodent NAT-1.

Applications:
Suitable for use in Western Blot, Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:500-1:2000
Immunohistochemistry: 1:50-1:200
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.